Skip to main content
. 2019 Mar 22;10:222. doi: 10.3389/fphar.2019.00222

Figure 2.

Figure 2

Spinal ERK1/2 phosphorylation (pERK) expression after preventive sigma-1 receptor antagonist MR309 treatment. Quantification and representative immunoblots of total ERK (tERK), pERK, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Experimental groups: Sham-Veh (n = 5), Sham-MR309-32 (n = 5), SCI-Veh (n = 4), SCI-MR309-16 (n = 5), and SCI-MR309-32 (n = 5). Protein expressions were normalized to GAPDH, and data are presented as a percentage respect to SCI-Veh mice. ANOVA analysis revealed significant differences at both 14 (F(4,23) = 3.54, p = 0.025) and 28 (F(4,24) = 3.65, p = 0.022) days post-injury. a, b: groups not sharing a letter are significantly different, p < 0.05, by Duncan’s test; #: significant differences vs. SCI-Veh (p < 0.05, Duncan’s test). MR309 treatments prevent pERK upregulation observed in mild spinal cord injured mice at both 14 (A) and 28 (B) days post-injury. Control images were reused either for illustrative purposes or methodological purposes when several protein levels were assessed in one blot. Full-length blots are presented in Supplementary Figure S1.